NS 9283-d₄

[1]. Grupe M, et al. Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats. Biochemical pharmacology. 2013 Nov 15;86(10):1487-96.

[2]. Grupe M, et al. Neuropharmacological modulation of the P3-like event-related potential in a rat two-tone auditory discrimination task with modafinil and NS9283, a positive allosteric modulator of α4β2 nAChRs. Neuropharmacology. 2014 Apr;79:444-55.

[3]. Rode F, et al. Positive allosteric modulation of α4β2 nAChR agonist induced behaviour. Brain research. 2012 Jun 06;1458:67-75. [Content Brief]

[4]. Grupe M, et al. Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors. British Journal of Pharmacology. 2013;168:2000-2010. [Content Brief]

[5]. Zhu CZ, et al. Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats. Biochemical pharmacology. 2011 Oct 15;82(8):967-76.

[6]. Maurer JJ, et al. Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283. Psychopharmacology. 2017 Feb;234(3):475-484.

[7]. Mohler EG, et al. Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology. 2014 Jan;231(1):67-74.